This site displays a prototype of a “Web 2.0” version of the daily
Federal Register. It is not an official legal edition of the Federal
Register, and does not replace the official print version or the official
electronic version on GPO’s govinfo.gov.
The documents posted on this site are XML renditions of published Federal
Register documents. Each document posted on the site includes a link to the
corresponding official PDF file on govinfo.gov. This prototype edition of the
daily Federal Register on FederalRegister.gov will remain an unofficial
informational resource until the Administrative Committee of the Federal
Register (ACFR) issues a regulation granting it official legal status.
For complete information about, and access to, our official publications
and services, go to
About the Federal Register
on NARA's archives.gov.
The OFR/GPO partnership is committed to presenting accurate and reliable
regulatory information on FederalRegister.gov with the objective of
establishing the XML-based Federal Register as an ACFR-sanctioned
publication in the future. While every effort has been made to ensure that
the material on FederalRegister.gov is accurately displayed, consistent with
the official SGML-based PDF version on govinfo.gov, those relying on it for
legal research should verify their results against an official edition of
the Federal Register. Until the ACFR grants it official status, the XML
rendition of the daily Federal Register on FederalRegister.gov does not
provide legal notice to the public or judicial notice to the courts.
Notice
Enter a search term or FR citation e.g.
88 FR 38230 FR 78782024-13208USDA09/05/24RULE0503-AA39SORN
Choosing an item from
full text search results
will bring you to those results. Pressing enter in the search box
will also bring you to search results.
Choosing an item from
suggestions
will bring you directly to the content.
Only written comments and/or applications for a license which are received by the NHLBI Office of Technology Transfer and Development November 1, 2022 will be considered.
Table of Contents
Enhanced Content - Table of Contents
This table of contents is a navigational tool, processed from the
headings within the legal text of Federal Register documents.
This repetition of headings to form internal navigation links
has no substantive legal effect.
Document page views are updated periodically throughout the day and are
cumulative counts for this document. Counts are subject to sampling,
reprocessing and revision (up or down) throughout the day.
Page views
154
as of
11/18/2026 at 2:15 am EST
Other Formats
Enhanced Content - Other Formats
This document is also available in the following formats:
This PDF is FR Doc. 2022-22476 as it appeared on Public Inspection on
10/14/2022 at 8:45 am.
It was viewed
2
times while on Public Inspection.
If you are using public inspection listings for legal research, you
should verify the contents of the documents against a final, official
edition of the Federal Register. Only official editions of the
Federal Register provide legal notice of publication to the public and judicial notice
to the courts under 44 U.S.C. 1503 & 1507.
Learn more here.
Published Document: 2022-22476 (87 FR 62866)
This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.
AGENCY:
National Institutes of Health, HHS.
ACTION:
Notice.
SUMMARY:
The National Heart, Lung and Blood Institute (NHLBI), National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to Molecular Targeting Technologies, Inc. (MTTI); a Delaware corporation, with its principle place of business in West Chester, Pennsylvania, to practice the inventions embodied in the issued patents and patent applications listed in the Supplementary Information section of this notice.
DATES:
Only written comments and/or applications for a license which are received by the NHLBI Office of Technology Transfer and Development November 1, 2022 will be considered.
ADDRESSES:
Requests for copies of the patent applications, inquiries, and comments relating to the contemplated exclusive patent license should be directed to: Michael Davis, JD, Ph.D., Deputy Director, NHLBI OTTAD, 31 Center Drive Room 4A29, MSC2479, Bethesda, MD 20892-2479, phone number 301-451-9032, or
michael.davis4@nih.gov.
SUPPLEMENTARY INFORMATION:
The following and all continuing U.S. and foreign patents/patent applications thereof are the intellectual properties to be licensed under the prospective agreement to MTTI:
NIH Ref No.
Patent No. or patent application No.
Issue date
Filing date
Title
E-150-2016-0-US-01
62/333,427
May 9, 2019
Chemical Conjugates of Evans Blue Derivatives and Their Use as Radiotherapy and Imaging Agents.
E-150-2016-0-PCT-02
PCT/US2017/031696
May 9, 2017
Chemical Conjugates of Evans Blue Derivatives and Their Use as Radiotherapy and Imaging Agents.
E-150-2016-0-CN-03
201780029003X
November 9, 2018
Chemical Conjugates of Evans Blue Derivatives and Their Use as Radiotherapy and Imaging Agents.
E-150-2016-0-EP-04
3455206
November 4, 2020
May 9, 2017
Chemical Conjugates of Evans Blue Derivatives and Their Use as Radiotherapy and Imaging Agents.
E-150-2016-0-JP-05
2018-558662
TBD (Allowed)
May 9, 2017
Chemical Conjugates of Evans Blue Derivatives and Their Use as Radiotherapy and Imaging Agents.
E-150-2016-0-US-06
10,696,637
June 30, 2020
May 9, 2017
Chemical Conjugates of Evans Blue Derivatives and Their Use as Radiotherapy and Imaging Agents.
E-150-2016-0-SG-07
11201809982R
November 8, 2021
May 9, 2017
Chemical Conjugates of Evans Blue Derivatives and Their Use as Radiotherapy and Imaging Agents.
E-150-2016-0-CH-08
3455206
November 4, 2020
May 9, 2017
Chemical Conjugates of Evans Blue Derivatives and Their Use as Radiotherapy and Imaging Agents.
E-150-2016-0-DE-09
3455206
(Certificate No. 602017027023.7)
November 4, 2020
May 9, 2017
Chemical Conjugates of Evans Blue Derivatives and Their Use as Radiotherapy and Imaging Agents.
E-150-2016-0-FR-10
3455206
November 4, 2020
May 9, 2017
Chemical Conjugates of Evans Blue Derivatives and Their Use as Radiotherapy and Imaging Agents.
( printed page 62867)
E-150-2016-0-GB-11
3455206
November 4, 2020
May 9, 2017
Chemical Conjugates of Evans Blue Derivatives and Their Use as Radiotherapy and Imaging Agents.
E-150-2016-0-IE-12
3455206
November 4, 2020
May 9, 2017
Chemical Conjugates of Evans Blue Derivatives and Their Use as Radiotherapy and Imaging Agents.
E-150-2016-0-IT-13
3455206
November 4, 2020
May 9, 2017
Chemical Conjugates of Evans Blue Derivatives and Their Use as Radiotherapy and Imaging Agents.
E-150-2016-1-PCT-01
PCT/US2017/054863
October 3, 2017
Chemical Conjugates of Evans Blue Derivatives And Their Use As Radiotherapy And Imaging Agents.
E-150-2016-1-CN-02
201780095506.7
October 3, 2017
Chemical Conjugates of Evans Blue Derivatives And Their Use As Radiotherapy And Imaging Agents.
E-150-2016-1-EP-03
17928082.1
October 3, 2017
Chemical Conjugates of Evans Blue Derivatives And Their Use As Radiotherapy And Imaging Agents.
E-150-2016-1-JP-04
2020-519137
October 3, 2017
Chemical Conjugates of Evans Blue Derivatives And Their Use As Radiotherapy And Imaging Agents.
E-150-2016-1-SG-05
112020002882V
October 3, 2017
Chemical Conjugates of Evans Blue Derivatives And Their Use As Radiotherapy And Imaging Agents.
E-150-2016-1-US-06
10,981,866
April 20, 2021
October 3, 2017
Chemical Conjugates of Evans Blue Derivatives And Their Use As Radiotherapy And Imaging Agents.
E-150-2016-1-HK-07
62020015610.2
October 3, 2017
Chemical Conjugates of Evans Blue Derivatives And Their Use As Radiotherapy And Imaging Agents.
The patent rights in these inventions have been assigned to the Government of the United States of America. The prospective patent license may be granted in a field of use directed to radiotherapeutics for nasopharyngeal cancer and the extent of the exclusive license may be territorially restricted to the United States, its Territories, Commonwealths and Possessions; and Asia.
The invention pertains to a radiotherapeutics against cancers that express somatostatin receptor. Radionuclide therapy directed against tumors that express somatostatin receptors (SSTRs) has proven effective for the treatment of advanced, low- to intermediate-grade neuroendocrine tumors. The subject radiotherapeutic covered by the patent estate includes a somatostatin (SST) peptide derivative like octreotate (TATE), conjugated to an Evans Blue (EB) analog, and further chelated via DOTA to therapeutic radionuclide177
Lu, a beta emitter. The EB analog reversibly binds to circulating serum albumin and improves the pharmacokinetics of SST peptide derivatives and reduce peptide-receptor radionuclide therapy toxicity. EB analog conjugated to octreotate (EB-TATE) has been shown by the inventors to provide reversible albumin binding
in vivo
and extended half-life in circulation. When EB-TATE is slowly released into the tumor microenvironment, tumor uptake and internalization into SSTR positive tumors resulted in delivery of radioactive particles and tumor cell killing. EB-TATE displayed significantly more favorable pharmacokinetics than TATE alone by achieving higher tumor to non-tumor penetration as evidenced by positron emission tomography.
Complete applications for a license in the prospective field of use that are timely filed in response to this notice will be treated as objections to the grant of the contemplated exclusive patent license.
Comments and objections submitted to this notice will not be made available for public inspection and, to the extent permitted by law, will not be released under the
Freedom of Information Act,5 U.S.C. 552.
Michael D. Davis,
Deputy Director, National Heart, Lung, and Blood Institute, Office of Technology Transfer and Development.